Jean‐Pierre Delord - Researcher Profile

Publications

2 shown

Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study

Aurélien Marabelle , Marwan Fakih , Juanita Lopez +18 more

2020 The Lancet Oncology 2300 citations

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

Ezra E.W. Cohen , Denis Soulières , Christophe Le Tourneau +97 more

There are few effective treatment options for patients with recurrent or metastatic head-and-neck squamous cell carcinoma. Pembrolizumab showed antitumour activity and manageabl...

2018 The Lancet 1593 citations

Frequent Co-Authors

Researcher Info

h-index: 2
Publications: 2
Citations: 3,893
Institution: Institut Claudius Regaud

External Links

ORCID Profile Google Scholar

Identifiers

ORCID: 0000-0001-7305-5561

Impact Metrics

h-index 2

h-index: Number of publications with at least h citations each.